Absorb bioresorbable vascular scaffold outcomes following implantation with routine intravascular imaging guidance

被引:3
|
作者
Costantini, Costantino R. [1 ,2 ]
Denk, Marcos A. [1 ,2 ]
De Macedo, Rafael M. [1 ,2 ]
Tarbine, Sergio G. [1 ,2 ]
Santos, Marcelo F. [1 ,2 ]
Luize, Marcio M. [1 ,2 ]
Folador, Joao C. [1 ,2 ]
Costantini, Costantino O. [1 ,2 ]
Stone, Gregg W. [3 ,4 ]
机构
[1] Hosp Cardiol Costantini, Rua Pedro Collere 890, BR-80320320 Curitiba, Parana, Brazil
[2] Fundacao Francisco Costantini, Curitiba, Parana, Brazil
[3] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA
[4] Cardiovasc Res Fdn, New York, NY USA
关键词
percutaneous coronary revascularization; bioabsorbable implants; intravascular imaging methods; coronary thrombosis; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; ELUTING STENT IMPLANTATION; MYOCARDIAL-INFARCTION; CLINICAL-OUTCOMES; ARTERY-DISEASE; ULTRASOUND; ANGIOGRAPHY; CONSENSUS; OPTIMIZATION;
D O I
10.1002/ccd.28699
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives We sought to describe the outcomes of BVS use from a single-center experience in which scaffold implantation was guided by intravascular imaging (ultrasound and/or optical coherence tomography) to identify and treat mechanical factors potentially related to BVS failure. Background The Absorb bioresorbable vascular scaffold (BVS) has been associated with an unexpectedly high incidence of thrombosis. Methods Between 11/2014 and 10/2016, 100 patients were treated with BVS. Intravascular imaging assessment before and after BVS implantation was performed in all cases. Results Mean age was 58.1 years; 88% were male, 31% had diabetes, and 28% presented with acute coronary syndromes. A total of 171 lesions in 141 vessels were treated with 190 BVS (mean 1.9 scaffolds/patient). Further intervention following intravascular imaging to optimize BVS implantation was required in 31% of patients. Procedure success was 100%. All patients completed a 1-year follow-up. The 1-year rate of target lesion failure was 4%, and there were no cases (0%) of scaffold thrombosis, myocardial infarction, or death. Conclusions In this real-world experience, the use of intravascular imaging to guide BVS implantation was associated with a high 1-year event-free survival rate, with no scaffold thrombosis.
引用
收藏
页码:48 / 55
页数:8
相关论文
共 50 条
  • [21] Clinical outcomes following bioresorbable scaffold implantation in small vessels
    Tanaka, Akihito
    Ruparelia, Neil
    Kawamoto, Hiroyoshi
    Sticchi, Alessandro
    Sato, Katsumasa
    Miyazaki, Tadashi
    Naganuma, Toru
    Chieffo, Alaide
    Carlino, Mauro
    Montorfano, Matteo
    Latib, Azeem
    Colombo, Antonio
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 207 : 59 - 61
  • [22] Routine use of optical coherence tomography in bioresorbable vascular scaffold implantation: insights on technique optimization and long-term outcomes
    Abdelaziz, Hesham K.
    Abuomara, Hossamaldin Z.
    Ali, Montasir H.
    Eichhofer, Jonas
    Patel, Billal
    Saad, Marwan
    CORONARY ARTERY DISEASE, 2019, 30 (04) : 263 - 269
  • [23] 5 Years of Serial Intravascular Imaging Outcomes of XINSORB Sirolimus- Eluting Bioresorbable Vascular Scaffold
    Wu, Yizhe
    Shen, Li
    Yin, Jiasheng
    Chen, Jiahui
    Ge, Lei
    Ge, Junbo
    JACC-CARDIOVASCULAR INTERVENTIONS, 2019, 12 (06) : 602 - 603
  • [24] The ABSORB Bioresorbable Vascular Scaffold: An Evolution or Revolution in Interventional Cardiology?
    Gogas, Bill D.
    Farooq, Vasim
    Onuma, Yoshinobu
    Serruys, Patrick W.
    HELLENIC JOURNAL OF CARDIOLOGY, 2012, 53 (04) : 301 - 309
  • [25] The Safety and Efficacy of Absorb Bioresorbable Vascular Scaffold: A Systematic Review
    Lu, Chang
    Filion, Kristian B.
    Eisenberg, Mark J.
    CLINICAL CARDIOLOGY, 2016, 39 (01) : 48 - 55
  • [26] The Absorb bioresorbable vascular scaffold for the treatment of coronary artery disease
    Collet, Carlos
    de Winter, Robbert J.
    Onuma, Yoshinobu
    Serruys, Patrick W.
    EXPERT OPINION ON DRUG DELIVERY, 2016, 13 (10) : 1489 - 1499
  • [27] Everolimus-eluting ABSORB bioresorbable vascular scaffold: present and future perspectives
    Brugaletta, Salvatore
    Garcia-Garcia, Hector M.
    Onuma, Yoshinobu
    Serruys, Patrick W.
    EXPERT REVIEW OF MEDICAL DEVICES, 2012, 9 (04) : 327 - 338
  • [28] Clinical outcomes of a real-world cohort following bioresorbable vascular scaffold implantation utilising an optimised implantation strategy
    Tanaka, Akihito
    Latib, Azeem
    Kawamoto, Hiroyoshi
    Jabbour, Richard J.
    Sato, Katsumasa
    Miyazaki, Tadashi
    Naganuma, Toru
    Mangieri, Antonio
    Pagnesi, Matteo
    Montalto, Claudio
    Chieffo, Alaide
    Carlino, Mauro
    Montorfano, Matteo
    Colombo, Antonio
    EUROINTERVENTION, 2017, 12 (14) : 1730 - 1737
  • [29] Percutaneous coronary interventions with the Absorb Bioresorbable vascular scaffold in real life: 1-year results from the FRANCE ABSORB registry
    Cayla, Guillaume
    Koning, Rene
    Fajadet, Jean
    Sainsous, Joel
    Carrie, Didier
    Elhadad, Simon
    Tarragano, Francois
    Lefevre, Thierry
    Ranc, Sylvain
    Ghostine, Said
    Garot, Philippe
    Marco, Frederic
    Maillard, Luc
    Motreff, Pascal
    Le Breton, Herve
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2019, 112 (02) : 113 - 123
  • [30] Absorb bioresorbable vascular scaffold: What have we learned after 5 years of clinical experience?
    Caiazzo, Gianluca
    Kilic, Ismail Dogu
    Fabris, Enrico
    Serdoz, Roberta
    Mattesini, Alessio
    Foin, Nicolas
    De Rosa, Salvatore
    Indolfi, Ciro
    Di Mario, Carlo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 201 : 129 - 136